Skip to search formSkip to main contentSkip to account menu

DG 5128

Known as: DG-5128 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1989
1989
The anesthetic-reducing property of medetomidine far exceeds that seen with other alpha 2-adrenergic agonists (e.g., clonidine… 
1988
1988
To study the possible role of alpha-2 receptors in in- tractable asthmatics, we investigated the ameliorative ef- fects of 2-(2… 
1987
1987
2[2-(4.5-Dihydro-1H-imidazol-2-yl)-1-phenylethyl] pyridine dihydrochloride sesquihydrate (DG-5128) is an alpha 2-specific… 
Highly Cited
1986
Highly Cited
1986
Effects of oral administration of DG-5128, a new oral hypoglycemic agent, on glycemic control after a mixed meal and an in vivo… 
1985
1985
Using rat cerebral cortex membranes, the inhibitory effect of DG-5128 against (3H)-clonidine binding was compared between low… 
1985
1985
Yohimbine (10(-8) to 10(-4) M) produced a concentration-dependent contraction of the isolated dog basilar artery. The maximal… 
1984
1984
DG-5128 (2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine dihydrochloride sesquihydrate) at concentrations up to 10… 
1982
1982
2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl] pyridine dihydrochloride sesquilhydrate (DG-5128) is a new orally effective… 
1982
1982
2-[2-(4,5-Dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine dihydrochloride sesquihydrate (GD-5128) is a new hypoglycemic agent…